Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$6.20M-$6.20MN/M vs Q2 2024 EPS Diluted-$151.29-$151.29N/M vs Q2 2024 Operating Income-$6,226,000N/M Operating Cash Flowderived-$7,093,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end